Our CSP® Cancer Profiler Pipeline
GeneCentric's Growing Portfolio of Cancer Profilers
By applying Cancer Subtyping Platform (CSP®) to specific types of cancer, GeneCentric has developed and is expanding on its’ portfolio of universal cancer subtypes/biomarkers – what we call ‘Profilers’ – for some of most prevalent and complex cancers.
CSP Profilers in the areas of lung cancer and head and neck cancer are available for immediate use. These diseases share common molecular subtypes, allowing GeneCentric to leverage its expertise across both programs to accelerate Profiler development. Currently under development are CSP Profilers for bladder and prostate cancer, which will be followed by colorectal and ovarian cancer.
Cancer Profilers Key
Current
Coming Soon
Future
Cancer Profilers Key
Current
Coming Soon
Future
Head & Neck Cancer Profiler (HNSP™)
Head and Neck Cancer, a group of cancers that starts within the mouth, nose, throat, larynx, sinuses, or salivary glands, is the seventh most common of all cancers. Because most majority begin in squamous cells which line the moist surfaces inside the head and neck areas, such cancers are also referred to as Head and Neck Squamous Cell Carcinomas (HNSCC).
These cancers comprise a heterogeneous disease with multiple tumor types, with correspondingly varying prognoses and treatment responses. Advanced HNSCC is associated with a 40-50 percent recurrence rate following primary treatment. Human papilloma virus (HPV) infection is an important risk factor, but infection is present in only a subset of cases and knowledge of HPV status alone is not sufficient to guide treatment. Better classification tools are needed to inform therapeutic choices and improve survival. To address this critical need, GeneCentric has applied our Cancer Subtyping Platform (CSP®) to develop a comprehensive profile of head and neck tumor subtypes that can guide drug development, clinical trials and patient treatment. The GeneCentric Head and Neck cancer Subtype Profiler (HNSP™) consists of five distinct subtypes, including one specific to HPV-related HNSCC, as determined through our research.
Faruki, et. al., GeneCentric Therapeutics, Inc. Data on file.
Lung Cancer Profilers (LSP™)
GeneCentric has developed two gene expression profilers (LSP 210 and LSP 220) that define molecular subtypes of the two most common forms of non-small cell lung cancer (NSCLC), squamous cell carcinoma, and adenocarcinoma.
Published studies have demonstrated that the subtypes, while indistinguishable by standard morphology, have different genetic, molecular and clinical attributes yielding immune profiles that have potential to drive drug response. The most recent study, published in the Journal of Thoracic Oncology (June 2017), demonstrated distinct differences among the subtypes in the immune landscape. GeneCentric is applying its LSs in a collaboration with Bristol-Myers Squibb to determine their potential to identify drug response populations to the immuno-therapy Opdivo® (nivolumab).
GeneCentric demonstrated initial validation of its subtyping approach with a genomic signature panel (LSP 110) that distinguishes NSCLC tumors from neuroendocrine tumors. Through an agreement with LabCorp, LSP 110 panel is commercially available as HistoPlus™.
Jrnl Thoracic Oncology. 2017 Mar 21.
